Supplementary Material

Journal name: Clinical Drug Investigation

Article title: Active Safety Surveillance of Four Types of COVID-19 Vaccines: a National

Study From Jordan

Short title: Safety of Four Types of COVID-19 Vaccines

Derar H. Abdel-Qader^{1,2*}, Hasan Abdel-Qader³, Jennifer Silverthorne⁴, Chuenjid Kongkaew⁵, Ahmad Z. Al Meslamani^{6,7}, Wail Hayajneh^{8,9}, Osama M. Abu Ata¹⁰, Walid Shnaigat², Salah AbuRuz^{11,12}, Mohannad Al Nsour¹³, Abdallah Alhariri¹⁴, Khaldoun Shnewer¹⁴, Mohanmad Da'ssan¹⁴ Nathir M. Obeidat¹⁵, Khaldoon E. Nusair¹⁶, Mothafer S. Jalamdeh¹⁷, Feras Hawari³, Khaldoun Khader³, Tareq Hakim³, Fatima A. Hammad³, Mustafa Al Qudah³, Mohanmad Asad¹³.

¹ Faculty of Pharmacy & Medical Sciences, University of Petra, Amman, Jordan.

² Al Rashid Hospital Center, Amman, Jordan.

³ Ministry of Health, Amman, Jordan.

⁴ Division of Pharmacy & Optometry, The University of Manchester, Manchester, UK.

⁵ Department of Pharmacy Practice, Naresuan University, Thailand.

⁶ AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emirates

⁷ College of Pharmacy, Al Ain University, Abu Dhabi, UAE.

⁸ School of Medicine, St. Louis University, USA.

⁹ School of Medicine, Jordan University of Science & Technology, Irbid, Jordan.

¹⁰ King Hussein Cancer Center, Amman, Jordan.

¹¹ Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, The United Arab Emirates University, Al Ain, United Arab Emirates.

¹² Department of Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman, Jordan.

¹³ Eastern Mediterranean Public Health Network (EMPHNET), Amman, Jordan.

¹⁴ Fourth Generation for Medical Laboratory, Amman, Jordan.

¹⁵ School of Medicine, The University of Jordan, Amman, Jordan.

¹⁶ King Abdullah University Hospital, Irbid, Jordan.

¹⁷ Prince Hamza Hospital, Amman, Jordan.

Table 1. Red flags criteria

Receiving a second dose of a	Experiencing an unsolicited	Having allergic reactions
vaccine that was different	adverse event that was not	
from the first dose	listed in the checklist	
Experiencing an adverse	Experiencing fever for more	Admitted to hospital after
event that lasted more than	than 3 days	vaccination
three days		
Recovered with sequelae	Experiencing moderate or	Death
	severe shortness of breath	

Table 3. Overall predictors for adverse events.

Independent variables (variables	AOR	95% CI for		P
VS reference)		AORs		values
Age (\geq 65 years Vs < 65 years)	0.437	0.425	0.449	0.001
Gender (male Vs females)	0.500	0.459	0.505	0.013
Previous COVID-19 infection	1.181	1.168	1.195	0.005
(infected Vs not infected)				
Influenza vaccine (vaccinated Vs not	1.143	1.121	1.166	0.001
vaccinated)				
Drug sensitivity (sensitive to a drug	1.557	1.518	1.597	0.005
Vs not sensitive to a drug)				
Food sensitivity (sensitive to food Vs	1.774	1.720	1.830	0.023
not sensitive to food)				
Smoking (smoker Vs not smoker)	1.139	1.126	1.153	0.001

Table 4. Predictors for adverse events reported by individuals who received BNT162b2 vaccine.

Independent variables (variables	AOR	95% CI for		P
VS reference)		AORs		values
Age (\geq 65 years Vs < 65 years)	0.483	0.464	0.502	0.003
Gender (male Vs females)	0.580	0.573	0.587	0.001
Previous COVID-19 infection	1.379	1.360	1.399	0.002
(infected Vs not infected)				
Influenza vaccine (vaccinated Vs not	1.058	1.030	1.087	0.004
vaccinated)				
Drug sensitivity (sensitive to a drug	1.691	1.629	1.755	0.003
Vs not sensitive to a drug)				
Foor sensitivity (sensitive to food Vs	1.887	1.811	1.967	0.018
not sensitive to food)				
Smoking (smoker Vs not smoker)	1.141	1.125	1.158	0.008

Table 5. Predictors for adverse events reported by individuals who received BBIBP-CorV vaccine.

Independent variables (variables	AOR	95% CI for		P
VS reference)		AORs		values
Age (\geq 65 years Vs < 65 years)	1.969	1.866	2.078	0.004
Gender (male Vs females)	2.014	1.971	2.057	0.001
Previous COVID-19 infection	0.867	0.845	0.889	0.001
(infected Vs not infected)				
Influenza vaccine (vaccinated Vs not	0.896	0.857	0.938	0.001
vaccinated)				
Drug sensitivity (sensitive to a drug	0.498	0.477	0.520	0.001
Vs not sensitive to a drug)				
Foor sensitivity (sensitive to food Vs	0.514	0.485	0.520	0.028
not sensitive to food)				
Smoking (smoker Vs not smoker)	1.142	1.108	1.177	0.007

Table 6. Predictors for adverse events reported by individuals who received ChAdOx1 nCoV-19 vaccine.

Independent variables (variables VS	AOR	95% CI for		P
reference)		AORs		values
Age (\geq 65 years Vs < 65 years)	2.434	2.271	2.608	0.001
Gender (male Vs females)	2.546	2.483	2.611	0.001
Previous COVID-19 infection	0.886	0.852	0.920	0.001
(infected Vs not infected)				
Influenza vaccine (vaccinated Vs not	1.834	1.691	1.982	0.801
vaccinated)				
Drug sensitivity (sensitive to a drug	0.698	0.427	0.821	0.001
Vs not sensitive to a drug)				
Food sensitivity (sensitive to food Vs	0.414	0.385	0.638	0.028
not sensitive to food)				
Smoking (smoker Vs not smoker)	1.325	1.112	1.502	0.001

Table 7. Predictors for adverse events reported by individuals who received Sputnik V vaccine.

Independent variables (variables	AOR	95% CI for		P
VS reference)		AORs		values
Previous COVID-19 infection	0.696	0.527	0.918	0.010
(infected Vs not infected)				
Drug sensitivity (sensitive to a drug	0.318	0.125	0.811	0.016
Vs not sensitive to a drug)				
Foor sensitivity (sensitive to food Vs	0.234	0.094	0.583	0.024
not sensitive to food)				
Smoking (smoker Vs not smoker)	1.102	1.017	1.366	0.014